PIK3CA Alterations in Middle Eastern Ovarian Cancers

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2009 Jul 30

PMID 19638206

Citations 23

Authors

Jehad Abubaker

Prashant Bavi

Wael Al-Haqawi

Zeenath Jehan

Adnan Munkarah

Shahab Uddin

Khawla S Al-Kuraya

Affiliations

Soon will be listed here.

Abstract

Background: PI3K/AKTsignaling pathway plays an important role in cell growth, proliferation, and tumorgenesis of various malignancies. This signaling pathway has been shown to be frequently altered in several human cancers including ovarian cancers. However the role of this oncogenic signaling pathway has not been explored in the Middle Eastern epithelial ovarian cancer (EOC). Therefore, we investigated PI3K/AKT genetic alterations such as PIK3CA amplification, PIK3CA mutation, PTEN protein loss and their relationships with various clinicopathological characteristics in 156 EOCs.

Results: Fluorescence in situ hybridization (FISH) technique and DNA sequencing were used to analyze PIK3CA amplification and mutation respectively. Expression of PIK3CA protein expression (p110 alpha), PTEN, p-AKT and Ki-67 was analyzed by immunohistochemistry. PIK3CA amplification was seen in 54 of 152 (35.5%) EOC cases analyzed; PIK3CA gene mutations in 6/153 EOC (3.9%); KRAS mutations in 3/154 EOC (1.9%), BRAF mutations in 3/156 EOC (1.9%), p53 mutation in 50/154 EOC (32.5%), and loss of PTEN protein expression in 33/144 EOC (22.9%). p110 alpha overexpression was associated with increased phosphorylation of AKT-Ser 473 and with the proliferation marker Ki-67.

Conclusion: Our data showed mutual exclusivity between the molecular event of PIK3CA amplification and mutations in PIK3CA, KRAS, BRAF genes, which suggests that each of these alterations may individually be sufficient to drive ovarian tumor pathogenesis independently. High prevalence of genetic alterations in PI3K/AKT pathway in a Middle Eastern ovarian carcinoma provides genetic evidence supporting the notion that dysregulated PI3K/AKT pathways play an important role in the pathogenesis of ovarian cancers.

Citing Articles

PTEN Tumor-Suppressor: The Dam of Stemness in Cancer.

Luongo F, Colonna F, Calapa F, Vitale S, Fiori M, De Maria R Cancers (Basel). 2019; 11(8).

PMID: 31366089 PMC: 6721423. DOI: 10.3390/cancers11081076.

Overexpression of thymic stromal lymphopoietin is correlated with poor prognosis in epithelial ovarian carcinoma.

Xu L, Guo Y, Xu N, Chen L, Zhu J, Liu N Biosci Rep. 2019; 39(5).

PMID: 31023965 PMC: 6522712. DOI: 10.1042/BSR20190116.

Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.

Ni D, Liu D, Zhang J, Lu S Int J Mol Sci. 2018; 19(1).

PMID: 29300353 PMC: 5796100. DOI: 10.3390/ijms19010151.

Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

Siraj A, Masoodi T, Bu R, Beg S, Al-Sobhi S, Al-Dayel F Am J Hum Genet. 2016; 98(6):1170-1180.

PMID: 27236916 PMC: 4908175. DOI: 10.1016/j.ajhg.2016.04.014.

HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.

Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y Oncotarget. 2016; 7(25):37966-37978.

PMID: 27177225 PMC: 5122364. DOI: 10.18632/oncotarget.9274.

References

Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke F, Fenic I . Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 2007; 450(4):387-95. DOI: 10.1007/s00428-006-0358-3. View

Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C . PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102. DOI: 10.1038/5042. View

Fishman D, Bozorgi K . The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res. 2002; 107:3-28. DOI: 10.1007/978-1-4757-3587-1_1. View

Jemal A, Tiwari R, Murray T, Ghafoor A, Samuels A, Ward E . Cancer statistics, 2004. CA Cancer J Clin. 2004; 54(1):8-29. DOI: 10.3322/canjclin.54.1.8. View

Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A . Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1708-18. DOI: 10.1158/1055-9965.EPI-05-0972. View

Wang H, Altomare D, Skele K, Poulikakos P, Kuhajda F, Di Cristofano A . Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 2005; 24(22):3574-82. DOI: 10.1038/sj.onc.1208463. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Cully M, You H, Levine A, Mak T . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6(3):184-92. DOI: 10.1038/nrc1819. View

Xing M . BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12(2):245-62. DOI: 10.1677/erc.1.0978. View

10.

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

11.

Uddin S, Siraj A, Al-Rasheed M, Ahmed M, Bu R, Myers J . Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab. 2008; 93(10):4088-97. DOI: 10.1210/jc.2008-0503. View

12.

Pfaffl M, Horgan G, Dempfle L . Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9):e36. PMC: 113859. DOI: 10.1093/nar/30.9.e36. View

13.

Sieben N, Macropoulos P, Roemen G, Kolkman-Uljee S, Fleuren G, Houmadi R . In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004; 202(3):336-40. DOI: 10.1002/path.1521. View

14.

Wang Y, Helland A, Holm R, Kristensen G, Borresen-Dale A . PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat. 2005; 25(3):322. DOI: 10.1002/humu.9316. View

15.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

16.

Chan W, Cheung K, Schorge J, Huang L, Welch W, Bell D . Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol. 2000; 156(2):409-17. PMC: 1850061. DOI: 10.1016/S0002-9440(10)64744-X. View

17.

Campbell I, Russell S, Choong D, Montgomery K, Ciavarella M, Hooi C . Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-81. DOI: 10.1158/0008-5472.CAN-04-2933. View

18.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

19.

Abubaker J, Bavi P, Al-Harbi S, Siraj A, Al-Dayel F, Uddin S . PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007; 21(11):2368-70. DOI: 10.1038/sj.leu.2404873. View

20.

Cantley L . The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-7. DOI: 10.1126/science.296.5573.1655. View